Neuraxis, INC (NRXS)
NeurAxis, Inc. (NRXS) is an American company specializing in neuromodulation therapy devices. Its primary offering is IB-Stim, a percutaneous electrical nerve field stimulation system engineered to alleviate functional abdominal pain associated with irritable bowel syndrome in patients aged 11 to 18. NeurAxis markets its solutions to healthcare providers, predominantly hospitals and clinics. The firm, headquartered in Carmel, Indiana, was established in 2011 and operated as Innovative Health Solutions, Inc. until its rebranding to NeurAxis, Inc. in March 2022.
Sector: Electromedical & Electrotherapeutic Apparatus
Industry: Biotechnology
NeurAxis, Inc.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
based on 12.56M shares outstanding
USNeurAxis, Inc. (NRXS) is an American company specializing in neuromodulation therapy devices.
Its primary offering is IB-Stim, a percutaneous electrical nerve field stimulation system engineered to alleviate functional abdominal pain associated with irritable bowel syndrome in patients aged 11 to 18. NeurAxis markets its solutions to healthcare providers, predominantly hospitals and clinics.
The firm, headquartered in Carmel, Indiana, was established in 2011 and operated as Innovative Health Solutions, Inc. until its rebranding to NeurAxis, Inc. in March 2022.
Leadership
Brian Carrico
President, Chief Executive Officer & Director
Dr. Adrian Miranda
Senior Vice President of Science & Technology and Chief Medical Officer
Dr. Thomas Carrico
Chief Regulatory Officer and Compliance & Privacy Officer
John Seale
Chief Financial Officer
Employees
24
Country
US
Sector
Healthcare
Website
neuraxis.com
| Insider | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
 Henrichs Timothy Robert | Chief Financial Officer | Purchase | 1.9K | $9.4K | Oct 8, 2026 |
 Carrico Brian Allen | Chief Executive Officer | Purchase | 268 | $1.3K | Oct 8, 2026 |
 Carrico Thomas Joeseph | CRO, CCO, CPO | Purchase | 328 | $1.6K | Oct 8, 2026 |
| Carrico Brian Allen | Chief Executive Officer | Grant/Award | 199.2K | -- | Aug 24, 2026 |
 Miranda Adrian | CMO, SVP Science & Tech | Conversion of Derivative | 337.2K | $2.34M | Aug 24, 2026 |
| Miranda Adrian | CMO, SVP Science & Tech | Grant/Award | 199.1K | -- | Aug 24, 2026 |
| Name | Shares | % | Source |
|---|---|---|---|
Rosalind Advisors, Inc. · also on 13F· may incl. warrants· filed Dec 2024 | 2.1M | 9.9% as filed | 13D |
Brian P. Hannasch · may incl. warrants· filed Jul 2025 | 1.1M | 9.1% | 13G |
Bigger Michael · joint filing· may incl. warrants· filed Aug 2026 | 831.7K | 6.6% | 13G |
AIGH Capital Management LLC | 519.9K | 4.1% | 13F |
Rosalind Advisors, Inc. | 508.1K | 4.0% | 13F |
VANGUARD CAPITAL MANAGEMENT LLC | 335.8K | 2.7% | 13F |
 MASIMO CORP 10% Owner | 289.8K | 2.3% | FORM 4 |
MONEY CONCEPTS CAPITAL CORP | 228.0K | 1.8% | 13F |
 Carrico Brian Allen Chief Executive Officer, Director | 227.6K | 1.8% | FORM 4 |
 Carrico Thomas Joeseph CRO, CCO, CPO | 199.7K | 1.6% | FORM 4 |
Insiders
- Henrichs Timothy RobertChief Financial Officer
- Carrico Brian AllenChief Executive Officer
- Carrico Thomas JoesephCRO, CCO, CPO
- Miranda AdrianCMO, SVP Science & Tech
- Watkins Bradley MitchellDirector
- Keyser Jane ElizabethDirector
- Ferge Kristin ADirector
- Aharon GilDirector
- MASIMO CORP10% Owner
based on 12.56M shares outstanding
US30d Avg
142.50K
60d Avg
152.34K
90d Avg
131.13K